Neuroimaging of disorders leading to dementia

CONTINUUM Lifelong Learning in Neurology

Volumn 14, Issue 4, 2008, Pages 144-163

  Masdeu, Joseph C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650419604     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000333204.72795.ed     Document Type: Article

References (40)

1. Alexander GE, Chen K, Pietrini P, et al. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002;159(5):738-745.
2. Auer DP, Pütz B, Gössl C, et al. Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. Radiology 2001;218(2):443-451.
3. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause taunegative frontotemporal dementia linked to chromosome 17. Nature 2006;442(7105): 916-919. (Pubitemid 44285946)
4. Beyer MK, Larsen JP, Aarsland D. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 2007;69(8):747-754.
5. Chui H, Zhang Q. Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology's practice parameters. Neurology 1997;49(4):925-935.
6. Chui HC, Zarow C, Mack WJ, et al. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol 2006;60(6):677-687.
7. Du AT, Schuff N, Zhu XP, et al. Atrophy rates of entorhinal cortex in AD and normal aging. Neurology 2003;60(3):481-486.
8. Eng JA, Frosch MP, Choi K, et al. Clinical manifestations of cerebral amyloid angiopathyrelated inflammation. Ann Neurol 2004;55(2):250-256.
9. Esiri MM, Wilcock GK, Morris JH. Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997;63(6):749-753.
10. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59(3):512-519.
11. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007;130(pt 10):2616-2635.
12. Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004;55(3):335-346.
13. Hejl A, Høgh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry 2002;73(4):390-394.
14. Herholz K, Schopphoff H, Schmidt M, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 2002;43(1):21-26.
15. Holodny AI, George AE, de Leon MJ, et al. Focal dilation and paradoxical collapse of cortical fissures and sulci in patients with normal-pressure hydrocephalus. J Neurosurg 1998;89(5):742-747.
16. Jack CR Jr, Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003;60(2):253-260.
17. Jagust W, Reed B, Mungas D, et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007;69(9):871-877.
18. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62(3):229-234.
19. Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006;66(1):41-48.
20. Kallenberg K, Schulz-Schaeffer WJ, Jastrow U, et al. Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. AJNR Am J Neuroradiol 2006;27(7):1459-1462.
21. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143-1153.
22. Likeman M, Anderson VM, Stevens JM, et al. Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias. Arch Neurol 2005;62(9):1410-1415.
23. Masdeu J, Aronson M. CT findings in early dementia. Gerontologist 1985;25:82.
24. Masdeu JC, Zubieta JL, Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer's disease. J Neurol Sci 2005;236(1-2):55-64.
25. Mendez MF, Shapira JS, McMurtray A, et al. Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol 2007;64(6):830-835.
26. Mosconi L, Brys M, Glodzik-Sobanska L, et al. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 2007;42(1-2):129-138.
27. Mukherjee O, Pastor P, Cairns NJ, et al. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol 2006;60(3):314-322.
28. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314(5796):130-133.
29. Ogino A, Kazui H, Miyoshi N, et al. Cognitive impairment in patients with idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Disord 2006;21(2):11-119.
30. Okamura N, Arai H, Higuchi M, et al. [18F]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2001;25(2):447-456.
31. O'Sullivan M, Ngo E, Viswanathan A, et al. Hippocampal volume is an independent predictor of cognitive performance in CADASIL. Neurobiol Aging 2007. PMID: 17963999.
32. Probst A, Taylor KI, Tolnay M. Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol 2007;114(4):335-345.
33. Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007;20(4):380-385.
34. Ringman JM, O'Neill J, Geschwind D, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 2007;130(pt 7): 1767-1776.
35. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68(20):1718-1725.
36. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002;1(1):13-21.
37. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001;286(17): 2120-2127.
38. Viswanathan A, Gschwendtner A, Guichard JP, et al. Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL. Neurology 2007;69(2): 172-179.
39. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14(1):1-26.
40. Whitwell JL, Przybelski SA, Weigand SD, et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007;130(pt 7):1777-1786.